QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 foghorn-therapeutics-q2-eps-028-beats-033-estimate-sales-7557m-beat-6498m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

 jmp-securities-reiterates-market-outperform-on-foghorn-therapeutics-maintains-9-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...

 foghorn-therapeutics-q1-eps-030-beats-031-estimate-sales-595m-beat-582m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

 jmp-securities-reiterates-market-outperform-on-foghorn-therapeutics-maintains-9-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform and maintains ...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 ...

 foghorn-therapeutics-presents-new-data-on-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-selective-ep300-degrader-programs

FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as th...

 jmp-securities-initiates-coverage-on-foghorn-therapeutics-with-market-outperform-rating-announces-price-target-of-9

JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform rat...

 foghorn-therapeutics-will-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-and-ep300-degrader-programs-at-2025-aacr-meeting-in-chicago-april-24-20-2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology c...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-13-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price...

 foghorn-therapeutics-fy-2024-gaap-eps-158-beats-161-estimate-sales-22602m-miss-30713m-estimate

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of ...

 b-riley-securities-initiates-coverage-on-foghorn-therapeutics-with-buy-rating-announces-price-target-of-10

B. Riley Securities analyst Kalpit Patel initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and anno...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-lowers-price-target-to-13

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION